Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity

Blood

Volumn 84, Issue 10, 1994, Pages 3261-3282

  Guinan, Eva C ^a   Gribben, John G ^b   Boussiotis, Vicki A ^b   Freeman, Gordon J ^b   Nadler, Lee M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; CD11B ANTIGEN; CD2 ANTIGEN; CD24 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; LEUKOSIALIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MEMBRANE ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TACROLIMUS; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; CELL ADHESION; CLONAL ANERGY; ETIOLOGY; GENE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; TUMOR; TUMOR IMMUNITY;

EID: 0027942023     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v84.10.3261.3261     Document Type: Review

References (244)

1. Schlossman SF, Boumsell L, Gilks JM, Harlan T, Kishimoto C, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF: CD antigens 1993. Blood 83:879, 1994
2. Bretscher P: The two-signal model of lymphocyte activation twenty-one years later. Immunol Today 13:74, 1992
3. Jenkins MK, Johnson JG: Molecules involved in T-cell costimulation. Curr Opin Immunol 5:361, 1993
4. Geppert T, Davis L, Gur H, Wacholtz M, Lipsky P: Accessory cell signals involved in T-cell activation. Immunol Rev 117:5, 1990
5. Weaver CT, Unanue ER: The costimulatory function of antigen-presenting cells. Immunol Today 11:49, 1990
6. Steinman RM, Young JW: Signals arising from antigen-presenting cells. Curr Opin Immunol 3:361, 1991
7. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15:321, 1994
8. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211, 1990
9. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191, 1993
10. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
11. Cohen J: Mounting a targeted strike on unwanted immune responses (news; comment). Science 257:751, 1992
12. Cohen J: New protein steals the show as 'costimulator' of T cells (news; comment). Science 262:844, 1993
13. Haynes BF, Denning SM, Le PT, Singer KH: Human intrathymic T cell differentiation. Semin Immunol 2:67, 1990
14. Rothenberg E: The development of functionally responsive T cells. Adv Immunol 51:85, 1992
15. Sprent J, Lo D, Gao E, Ron Y: T-cell selection in the thymus. Immunol Rev 111:173, 1988
16. Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271, 1991
17. Metlay J, Pure E, Steinman R: Control of the immune response at the level of antigen-presenting cells: A comparison of the function of dendritic cells and B lymphocytes. Adv Immunol 47:45, 1989
18. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403, 1993
19. Braciale T, Braciale V: Antigen presentation: Structural themes and functional variations. Immunol Today 12:124, 1991
20. Pierce S, Morris J, Grusby M, Kaumaya P, Buskirk A, Srinivasan M, Crump B, Smolenski L, Glimscher L: Antigen-presenting function of B lymphocytes. Immunol Rev 106:149, 1988
21. Hauser C, Katz S: Generation and characterization of T helper cells by primary in vitro sensitization using Langerhans cells. Immunol Rev 117:67, 1990
22. Pober JS, Cotran RS: Immunologic interactions of T lymphocytes with vascular endothelium. Adv Immunol 50:261, 1991
23. Hughes C, Savage C, Pober J: The endothelial cell as a regulator of T-cell function. Immunol Rev 117:85, 1990
24. Shimizu Y, Newman W, Tanaka Y, Shaw S: Lymphocyte interactions with endothelial cells. Immunol Today 13:106, 1992
25. Hemler M: VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol 8:365, 1990
26. Kishimoto T, Larson R, Corbi A, Dustin M, Staunton D, Springer T: The leukocyte integrins. Adv Immunol 46:149, 1991
27. Mackay CR, Imhof BA: Cell adhesion in the immune system. Immunol Today 14:99, 1993
28. Fougerolles AR, Springer TA: Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J Exp Med 175:185, 1992
29. Rothbard JB, Gefter ML: Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 9:527, 1991
30. Yewdell J, Bennink J: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 52:125, 1992
31. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601, 1989
32. Harding C, Leyva-Cobian F, Unanue ER: Mechanisms of antigen processing. Immunol Rev 106:77, 1988
33. Berzofsky J, Brett S, Streicher HZ, Takahashi H: Antigen processing for presentation to T lymphocytes: Functional mechanisms and implications for the T-cell repetoire. Immunol Rev 106:5, 1988
34. Janeway C: The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 10:645, 1992
35. Brodsky FM, Guagliardi LE: The cell biology of antigen processing and presentation. Annu Rev Immunol 9:707, 1991
36. Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11:213, 1993
37. Lorenz R, Allen P: Processing and presentation of self proteins. Immunol Rev 106:115, 1988
38. Sadegh-Nasseri S, Germain RN: How MHC class molecules work: Peptide-dependent completion of protein folding. Immunol Today 13:43, 1992
39. Monaco J: A molecular model of MHC class-I-restricted antigen processing. Immunol Today 13:173, 1992
40. Neefjes J, Ploegh H: Intracellular transport of MHC class II molecules. Immunol Today 13:179, 1992
41. Elliot T: How do peptides associate with MHC class I molecules? Immunol Today 12:386, 1991
42. Miceli MC, Parnes JR: The role of CD4 and CD8 in T cell activation and differentiation. Adv Immunol 53:59, 1993
43. Julius M, Maroun CR, Haughn L: Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signaling. Immunol Today 14:177, 1993
44. Jorgensen J, Reay P, Ehrich E, Davis M: Molecular components of T-cell recognition. Annu Rev Immunol 10:835, 1992
45. Leiden E: Transcriptional regulation of T cell receptor genes. Annu Rev Immunol 11:539, 1993
46. Ullman K, Northrup JP, Verweij CL, Crabtree GC: Transmission of signals from T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function. Annu Rev Immunol 8:421, 1990
47. Altman A, Coggeshall KM, Mustelin T: Molecular events mediating T cell activation. Adv Immunol 48:227, 1990
48. Bierer B, Burakoff S: T-lymphocyte activation: the biology and function of CD2 and CD4. Immunol Rev 111:267, 1989
49. Fraser JD, Straus D, Weiss A: Signal transduction events leading to T-cell lymphokine gene expression. Immunol Today 14:357, 1993
50. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 169:1042, 1970
51. June CH, Jackson KM, Ledbetter JA, Leiden JM, Lindsten T, Thompson CB: Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes. J Autoimmunity 2:55, 1989
52. Bjorndahl JM, Sung SS, Hansen JA, Fu SM: Human T cell activation: Differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies. Eur J Immunol 19:881, 1989
53. Cerdan C, Martin Y, Brailly H, Courcoul M, Flavetta S, Costello R, Mawas C, Birg F, Olive D: IL-1 alpha is produced by T lymphocytes activated via the CD2 plus CD28 pathways. J Immunol 146:560, 1991
54. Cerdan C, Martin Y, Courcoul M, Brailly H, Mawas C, Birg F, Olive D: Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-transcriptional regulation. J Immunol 149:2255, 1992
55. Cerdan C, Razanajaona D, Martin Y, Courcoul M, Pavon C, Mawas C, Olive D, Birg F: Contributions of the CD2 and CD28 T lymphocyte activation pathways to the regulation of the expression of the colony-stimulating factor (CSF-1) gene. J Immunol 149:373, 1992
56. Boussiotis VA, Freeman GJ, Gray GS, Gribben JG, Nadler LM: B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 178:1753, 1993
57. Damle NK, Klussman K, Leytze G, Ochs HD, Aruffo A, Linsley PS, Ledbetter JA: Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell Immunol 148:144, 1993
58. Damle NK, Klussman K, Linsley PS, Aruffo A: Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J Immunol 148:1985, 1992
59. Damle NK, Klussman K, Linsley PS, Aruffo A, Ledbetter JA: Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7. J Immunol 149:2541, 1992
60. van Seventer G, Shimuzu Y, Horgan K, Shaw S: The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144:4579, 1990
61. van Seventer G, Shimizu Y, Horgan K, Ginther Luce G, Webb D, Shaw S: Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: Demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation. Eur J Immunol 21:1711, 1991
62. Koyasu S, Lawton T, Novick D, Recny MA, Siliciano RF, Wallner BP, Reinherz EL: Role of interaction of CD2 molecules with lymphocyte function-associated antigen 3 in T-cell recognition of nominal antigen. Proc Natl Acad Sci USA 87:2603, 1990
63. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
64. Jenkins MK: The role of cell division in the induction of clonal anergy. Immunol Today 13:69, 1992
65. Schwartz RH, Mueller DL, Jenkins MK, Quill H: T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 54:605, 1989
66. Charton B, Auchincloss H, Fathman CG: Mechanisms of transplantation tolerance. Annu Rev Immunol 12:707, 1994
67. Aruffo A, Seed B: Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 84:8573, 1987
68. Martin PJ, Ledbetter JA, Morishita Y, June CH, Beatty PG, Hansen JA: A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J Immunol 33:81, 1986
69. Kozbor D, Moretta A, Messner HA, Moretta L, Croce CM: Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells. J Immunol 138:4128, 1987
70. Hansen JA, Martin PJ, Nowinski RC: Monoclonal antibodies identifying a novel T-cell antigen and Ia antigens of human lymphocytes. Immunogenetics 10:247, 1980
71. Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB: CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol 144:1646, 1990
72. Pierres A, Cerdan C, Lopez M, Mawas C, Olive D: "CD3 low" human thymocyte populations can readily be triggered via the CD2 and/or CD28 activation pathways whereas the CD3 pathway remains nonfunctional. J Immunol 144:1202, 1990
73. Damle NK, Mohagheghpour N, Hansen JA, Engleman EG: Alloantigen-specific cytotoxic and suppressor T lymphocytes are derived from phenotypically distinct precursors. J Immunol 131:2296, 1983
74. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB: T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol Cell Biol 7:4472, 1987
75. Hara T, Fu SM, Hansen JA: A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med 161:1513, 1985
76. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P: Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol 135:2331, 1985
77. Yamada H, Martin PJ, Bean MA, Braun MP, Beatty PG, Sadamoto K, Hansen JA: Monoclonal antibody 9.3 and anti-CD11 antibodies define reciprocal subsets of lymphocytes. Eur J Immunol 15:1164, 1985
78. Freedman MS, Ruijs TC, Blain M, Antel JP: Phenotypic and functional characteristics of activated CD8+ cells: A CD11b-CD28- subset mediates noncytolytic functional suppression. Clin Immunol Immunopathol 60:254, 1991
79. Koide J, Engleman EG: Differences in surface phenotype and mechanism of action between alloantigen-specific CD8+ cytotoxic and suppressor T cell clones. J Immunol 144:32, 1990
80. Li SG, Ottenhoff TH, Van den Elsen P, Koning F, Zhang L, Mak T, De Vries RR: Human suppressor T cell clones lack CD28. Eur J Immunol 20:1281, 1990
81. Baroja ML, Lorre K, Van Vaeck F, Ceuppens JL: The anti-T cell monoclonal antibody 9.3 (anti-CD28) provides a helper signal and bypasses the need for accessory cells in T cell activation with immobilized anti-CD3 and mitogens. Cell Immunol 120:205, 1989
82. Jenkins MK, Taylor PS, Norton SD, Urdahl KB: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 147:2461, 1991
83. Gmunder H, Lesslauer W: A 45-kDa human T-cell membrane glycoprotein functions in the regulation of cell proliferative responses. Eur J Biochem 142:153, 1984
84. de Jong R, Stokkers P, Lamme E, Kool JM, Borst F, Brouwer M, Miedema F, van Lier RA: Regulation of T-cell differentiation by CD2 and CD28 accessory molecules. Immunology 74:175, 1991
85. Carabasi MH, Di Santo JP, Yang SY, Dupont B: Activation of peripheral CD8+ T lymphocytes via CD28 plus CD2: Evidence for IL-2 gene transcription mediated by CD28 activation. Tissue Antigens 37:26, 1991
86. Van Lier RA, Brouwer M, Aarden LA: Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol 18:167, 1988
87. Ledbetter JA, Rabinovtich PS, Hellstrom I, Hellstrom KE, Grosmaire LS, June CH: Role of CD2 cross-linking in cytoplasmic calcium responses and T cell activation. Eur J Immunol 18:1601, 1988
88. Civil A, Geerts M, Aarden LA, Verweij CL: Evidence for a role of CD28RE as a response element for distinct mitogenic T cell activation signals. Eur J Immunol 22:3041, 1992
89. Costello R, Lipcey C, Algarte M, Cerdan C, Baeuerle PA, Olive D, Imbert J: Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. Cell Growth Differ 4:329, 1993
90. Fraser JD, Irving BA, Crabtree GR, Weiss A: Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251:313, 1991
91. Fraser JD, Weiss A: Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28. Mol Cell Biol 12:4357, 1992
92. Fraser JD, Newton ME, Weiss A: CD28 and T cell antigen receptor signal transduction coordinately regulate interleukin 2 gene expression in response to superantigen stimulation. J Exp Med 175:1131, 1992
93. Ghosh P, Tan TH, Rice NR, Sica A, Young HA: The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc Natl Acad Sci USA 90:1696, 1993
94. Hutchcroft JE, Bierer BE: Activation-dependent phosphorylation of the T-lymphocyte surface receptor CD28 and associated proteins. Proc Natl Acad Sci USA 91:3260, 1994
95. June CH, Ledbetter JA, Lindsten T, Thompson CB: Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes. J Immunol 143:153, 1989
96. Johnson JG, Jenkins MK: Co-stimulatory functions of antigen-presenting cells. J Invest Dermatol 99:62, 1992
97. Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, Lindsten T, Thompson CB, June CH: CD28 ligation in T-cell activation: Evidence for two signal transduction pathways. Blood 75:1531, 1990
98. Nunes J, Klasen S, Franco MD, Lipcey C, Mawas C, Bagnasco M, Olive D: Signalling through CD28 T-cell activation pathway involves an inositol phospholipid-specific phospholipase C activity. Biochem J 293:835, 1993
99. Prasad KVS, Cai Y-C, Rabb M, Duckworth B, Cantley L, Shoelson SE, Rudd CE: T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA 91:2834, 1994
100. Truitt KE, Hicks CM, Imboden JB: Stimulation of CD28 triggers an association between CD28 and phosphatidylinositol 3-kinase in Jurkat T cells. J Exp Med 179:1071, 1994
101. Vandenberghe P, Freeman GJ, Nadler LM, Fletcher MC, Kamoun M, Turka LA, Ledbetter JA, Thompson CB, June CH: Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. J Exp Med 175:951, 1992
102. Ward SG, Westwick J, Hall ND, Sansom DM: Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur J Immunol 23:2572, 1993
103. Rudd CE, Janssen O, Cai Y, daSilva AJ, Raab M, Prasad KVS: Two-step TCRζ/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol Today 15:225, 1994
104. Guba SC, Stella G, Turka LA, June CH, Thompson CB, Emerson SG: Regulation of interleukin 3 gene induction in normal human T cells. J Clin Invest 84:1701, 1989
105. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/ cytokines. Proc Natl Acad Sci USA 86:1333, 1989
106. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB: Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 244:339, 1989
107. Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW: Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609, 1993
108. Atluru S, Atluru D: Evidence that genistein, a protein-tyrosine kinase inhibitor, inhibits CD28 monoclonal-antibody-stimulated human T cell proliferation. Transplantation 51:448, 1991
109. Bierer BE, Schreiber SL, Burakoff SJ: The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. Eur J Immunol 21:439, 1991
110. Bloemena E, Van Oers RH, Weinreich S, Stilma-Meinesz AP, Schellekens PT, Van Lier RA: The influence of cyclosporin A on the alternative pathways of human T cell activation in vitro. Eur J Immunol 19:943, 1989
111. Galvin F, Freeman GJ, Razi-Wolf Z, Benacerraf B, Nadler L, Reiser H: Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. Eur J Immunol 23:283, 1993
112. Hess AD, Bright EC: The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine. Transplantation 51:1232, 1991
113. Linsley PS, Clark EA, Ledbetter JA: T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 87:5031, 1990
114. Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM: B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol 139:3260, 1987
115. Yokochi T, Holly RD, Clark EA: B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 128:823, 1982
116. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM: B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143:2714, 1989
117. Freeman GJ, Gray GS, Gimmi CD, Lombard DB, Zhou LJ, White M, Fingeroth JD, Gribben JG, Nadler LM: Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 174:625, 1991
118. Freeman GJ, Disteche CM, Gribben JG, Adler DA, Freedman AS, Dougery J, Nadler LM: The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3-3q21. Blood 79:489, 1992
119. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM: Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: A potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 137:429, 1991
120. Azuma M, Yssel H, Phillips JH, Spits H, Lanier LL: Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med 177:845, 1993
121. Friccius H, Siegels-Hubenthal P, Rehbein A, Schlotz E, Pawelec G: Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7. Cell Immunol 151:283, 1993
122. Sansom DM, Hall ND: B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur J Immunol 23:295, 1993
123. Yssel H, Schneider PV, Lanier LL: Interleukin-7 specifically induces the B7/BB1 antigen on human cord blood and peripheral blood T cells and T cell clones. Int Immunol 5:753, 1993
124. Augustin M, Dietrich A, Niedner R, Kapp A, Schopf E, Ledbetter JA, Brady W, Linsley PS, Simon JC: Phorbol-12-myristate-13-acetate-treated human keratinocytes express B7-like molecules that serve a costimulatory role in T-cell activation. J Invest Dermatol 100:275, 1993
125. Fleming TE, Mirando WS, Trefzer U, Tubesing KA, Elmets CA: In situ expression of a B7-like adhesion molecule on keratinocytes from human epidermis. J Invest Dermatol 101:754, 1993
126. Nickoloff BJ, Mitra RS, Lee K, Turka LA, Green J, Thompson C, Shimizu Y: Discordant expression of CD28 ligands, BB-1, and B7 on keratinocytes in vitro and psoriatic cells in vivo. Am J Pathol 142:1029, 1993
127. Symington FW, Brady W, Linsley PS: Expression and function of B7 on human epidermal Langerhans cells. J Immunol 150:1286, 1993
128. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM: In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 83:793, 1994
129. Vandenberghe P, Delabie J, de Boer M, De Wolf-Peeters C, Ceuppens JL: In situ expression of B7/BB1 on antigen-presenting cells and activated B cells: An immunohistochemical study. Int Immunol 5:317, 1993
130. Reiser H, Freeman GJ, Razi-Wolf Z, Gimmi CD, Benacerraf B, Nadler LM: Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 89:271, 1992
131. Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK: The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 149:1556, 1992
132. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607, 1992
133. Koulova L, Clark EA, Shu G, Dupont B: The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med 173:759, 1991
134. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721, 1991
135. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM: B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 88:6575, 1991
136. Galvin F, Freeman GJ, Razi-Wolf Z, Hall W Jr, Benacerraf B, Nadler L, Reiser H: Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol 149:3802, 1992
137. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 175:353, 1992
138. Damle NK, Linsley PS, Ledbetter JA: Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7. Eur J Immunol 21:1277, 1991
139. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 90:6586, 1993
140. Gross JA, St John T, Allison JP: The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol 144:3201, 1990
141. Freeman G, Borriello F, Hodes R, Reiser H, Gribben JG, Ng J, Kim, Goldberg J, Hathcock K, Laszlo G, Nadler LM, Sharpe A: Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 178:2185, 1993
142. Brunet J-F, Denizot F, Luciani M-F, Roux-Dosseto M, Suzan M, Mattei M-G, Golstein P: A new member of the immunoglobulin superfamily-CTLA-4. Nature 328:267, 1987
143. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, Lombard DB, Freeman GJ, Nadler LM, Gray GS, Thompson CB, June CH: Characterization of CTLA-4 structure and expression on human T cells. J Immunol 151:3489, 1993
144. Balzano C, Buonavista N, Rouvier E, Golstein P: CTLA-4 and CD28: Similar proteins, neighbouring genes. Int J Cancer Suppl 7:28, 1992
145. Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P: CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 147:1037, 1991
146. Lafage-Pochitaloff M, Costello R, Couez D, Simonetti J, Mannoni P, Mawas C, Olive D: Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34. Immunogenetics 31:198, 1990
147. Buonavista N, Balzano C, Pontarotti P, Le Paslier D, Golstein P: Molecular linkage of the human CTLA4 and CD28 Ig-superfamily genes in yeast artificial chromosomes. Genomics 13:856, 1992
148. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561, 1991
149. Freeman GJ, Lombard DB, Gimmi CD, Brod SA, Lee K, Laning JC, Hafler DA, Dorf ME, Gray GS, Reiser H, June CH, Thompson CB, Nadler LM: CTLA-4 and CD28 mRNA are coexpressed in most T cells after activation. Expression of CTLA-4 and CD28 mRNA does not correlate with the pattern of lymphokine production. J Immunol 149:3795, 1992
150. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK: Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176:1595, 1992
151. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Ke X-Y, Gray GS, Nadler LM: CTLA4 mediates antigen specific apoptosis of human T cells. Proc Natl Acad Sci USA (in press)
152. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 177:165, 1993
153. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, MacKnight AJ, Kim J, Du L, Lomb ard DB, Gray GS, Nadler LM, Sharpe AH: Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907, 1993
154. Wu Y, Guo Y, Liu Y: A major costimulatory molecule on antigen-presenting cells, CTLA4 ligand A, is distinct from B7. J Exp Med 178:1789, 1993
155. Razi-Wolf Z, Galvin F, Gray G, Reiser H: Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. Proc Natl Acad Sci USA 90:11182, 1993
156. Lenschow DJ, Su GH-T, Zuckerman LA, Nabavi N, Jellis CL, Gray GS, Miller J, Bluestone JA: Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA 90:11054, 1993
157. Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray GS, Nadler LM: Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation. Proc Natl Acad Sci USA 90:11059, 1993
158. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76, 1993
159. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo V Jr, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation (see comments). Science 262:909, 1993
160. Engel P, Gribben JG, Freeman G, Zhou L-J, Nozawa Y, Abe M, Nadler LM, Wakasa H, Tedder TF: The B7-2 (B70) costimulatory molecule of monocytes and activated B lymphocytes is the CD86 differentiation antigen. Blood 84:1402, 1994
161. Freeman GJ, Edelhoff S, Disteche CM, Wong S, Jellis C, Rennert P, Gray GS, Nadler LM: Genomic structure and chromosomal localization of human and murine B7-2. (submitted)
162. Selvakumar A, Mohanraj BK, Eddy RL, Shows TB, White PC, Dupont B: Genomic organization and chromosomal location of the human gene encoding the B-lymphocyte activation antigen B7. Immunogenetics 36:175, 1992
163. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ: Identification of an alternative CTLA-4 ligand costimulatory for T cell activation (see comments). Science 262:905, 1993
164. Mueller D, Jenkins MK, Schwartz RH: Clonal expansion vs. functional clonal inactivation. Annu Rev Immunol 7:445, 1989
165. Robey E, Urbain J: Tolerance and immune regulation. Immunol Today 12:175, 1991
166. Greenen V, Kroemer G: Multiple ways to cellular immune tolerance. Immunol Today 14:573, 1993
167. Miller JFAP, Morahan G: Peripheral T cell tolerance. Annu Rev Immunol 10:51, 1992
168. Jenkins M, Schwartz R: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165:302, 1987
169. Jenkins MK, Ashwell JD, Schwartz RH: Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 140:3324, 1988
170. Sigal NH, Dumont FJ: Cyclosporin A, FK-506, and rapamycin: Pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10:519, 1992
171. Gribben JG, Guinan EC, Boussiotis VA, Barber M, Gray G, Freeman G, Nadler LM: Blockade of B7 family costimulatory molecules significantly reduces alloantigen specific precursor helper T cell frequency. (submitted)
172. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g (see comments). Science 257:789, 1992
173. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 178:1801, 1993
174. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, Bailey T, Bolling SF, Thompson CB: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 89:11102, 1992
175. Blazar BR, Taylor PA, Linsley PS, Vallera DA: In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83:3815, 1994
176. Beverly B, Kang SM, Lenardo MJ, Schwartz RH: Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4:661, 1991
177. Boussiotis VA, Freeman GJ, Griffin JD, Gray GS, Gribben JG, Nadler LM: CD2 is involved in maintenance and reversal of human alloantigen specific clonal anergy. J Exp Med (in press)
178. Ferrara JLM, Deeg HJ: Mechanisms of disease. Graft-versus-host disease. N Engl J Med 324:667, 1991
179. Rosenberg S (ed): Gene Therapy of Cancer. Philadelphia, PA, Lippincott, 1992
180. Russell SJ: Lymphokine gene therapy for cancer. Immunol Today 11:196, 1990
181. Topalian SL, Rosenberg SA: Tumor-infiltrating lymphocytes:evidence for specific immune reactions against growing cancers in mice and humans, in DeVita VTJ, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1990, p 19
182. Lanzavecchia A: Identifying strategies for immune intervention. Science 260:937, 1993
183. Urban J, Schreiber H: Tumor antigens. Annu Rev Immunol 10:617, 1992
184. Pardoll DM: Cancer vaccines. Immunol Today 14:310, 1993
185. Boon T, Coulie P, Marchand M, Weynants P, Wolfel T, Brichard V: Genes coding for tumor rejection antigens: perspectives for specific immunotherapy, in DeVita VTJ, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1994, p 53
186. Boon T, Cerottini JC, Eynde B, Bruggen P, Pel AV: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337, 1994
187. Delabie J, Ceuppens JL, Vandenberghe P, de Boer M, Coorevits L, De Wolf-Peeters C: The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines. Blood 82:2845, 1993
188. Freedman AS, Nadler LM: Cell surface markers in hematologic malignancies. Semin Oncol 14:193, 1987
189. Freedman AS, Boyd AW, Berrebi A, Horowitz JC, Levy DN, Rosen KJ, Daley J, Slaughenhoupt B, Levine H, Nadler L: Expression of B cell activation antigens on normal and malignant B cells. Leukemia 1:9, 1986
190. Freedman AS, Griffin JD, Nadler LM: Ontogeny of leukocytes and leukemias.
191. Freedman AS: Expression and function of adhesion receptors on normal B cells and B cell non-Hodgkin's lymphomas. Semin Hematol 30:318, 1993
192. Griffin JD, Ritz J, Nadler LM, Schlossman SF: Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 68:932, 1981
193. Anderson KC, Slaughenhoupt B, Bates MP, Pinkus G, O'Hara C, Schlossman SF, Nadler LM: Expression of human B cell associated antigens on leukemia and lymphomas: A model of human B cell differentiation. Blood 63:1424, 1984
194. Chen L, Linsley PS, Hellstrom KE: Costimulation of T cells for tumor immunity. Immunol Today 14:483, 1993
195. Elliot BE, Carlow DA, Rodricks A-M, Wade A: Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53:181, 1989
196. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL: Natural history of HLA expression during tumor development. Immunol Today 14:491, 1993
197. Nathan C: Interferon and inflammation, in Gallin JI, Goldstein IM, Snyderman R (eds): Inflammation. Basic Principles and Clinical Correlates. New York, NY, Raven, 1992, p 260
198. Borden EC, Sondel PM: Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65:800, 1990
199. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, Sakata T: Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Science USA 86:9456, 1989
200. Greenberg P: Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281, 1991
201. Beun GDM, van de Velde CJH, Fleuren GJ: T-cell based cancer immunotherapy: Direct or redirected tumor-cell recognition? Immunol Today 15:11, 1994
202. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
203. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
204. Levy R, Miller RA: Therapy of lymphoma directed at idiotypes. Monogr Natl Cancer Inst 10:61, 1990
205. Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantarjian HM, Deisseroth AB, Emerson SG: Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 88:2131, 1991
206. Bateman WJ, Fiera R, Matthews N, Morris AG: Inducibility of class II major histocompatibility complex antigens by interferon gamma is associated with reduced tumorigenicity in C3H mouse fibroblasts transformed by v-Ki-ras. J Exp Med 173:193, 1991
207. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687, 1993
208. Townsend SE, Allison JP: Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells (see comments). Science 259:368, 1993
209. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523, 1994
210. Matulonis U, Dosiou D, Mauch P, Freeman G, Lamont C, Nadler L: Rejection of myeloid leukemia cells after B7-1 transfection. (submitted)
211. Guo Y, Wu M, Chen H, Wang X, Liu G, Ma J, Sy M: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 263:518, 1994
212. Tan R, Teh SJ, Ledbetter JA, Linsley PS, Teh HS: B7 co-stimulates proliferation of CD4-8+ T lymphocytes but is not required for the deletion of immature CD4+8+ thymocytes. J Immunol 149:3217, 1992
213. Ranheim EA, Kipps TJ: Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177:925, 1993
214. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM: IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151:1224, 1993
215. Romano MF, Turco MC, Stanziola A, Giarrusso PC, Petrella A, Tassone P, van Lier R, Venuta S, Formisano S: Defect of interleukin-2 production and T cell proliferation in atopic patients: Restoring ability of the CD28-mediated activation pathway. Cell Immunol 148:455, 1993
216. Silverman ED, Somma C, Khan MM, Melmon KL, Engleman EG: Abnormal T suppressor cell function in juvenile rheumatoid arthritis. Arthritis Rheum 33:205, 1990
217. Wyss-Coray T, Mauri-Hellweg D, Baumann K, Bettens F, Grunow R, Pichler WJ: The B7 adhesion molecule is expressed on activated human T cells: Functional involvement in T-T cell interactions. Eur J Immunol 23:2175, 1993
218. Harlan DM, Hengartner H, Huang ML, Kang YH, Abe R, Moreadith RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ, Nadler LM, June CH, Aichele P: Mice expressing both B7 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T lymphocyte unresponsiveness. Proc Natl Acad Sci USA 91:3137, 1994
219. Guerder S, Meyerhoff J, Flavell R: The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. Immunity 1:155, 1994
220. Zamvil S, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8:579, 1990
221. Warren RP, Storb R, Thomas ED, Su PJ, Mickelson EM, Weiden PL: Autoimmune and allimmune phenomena in patients with aplastic anemia: Cytotoxicity against autologous lymphocytes and lymphocytes from HLA identical siblings. Blood 56:683, 1980
222. Camitta B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D: Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood 62:883, 1983
223. Champlin R, Ho W, Gale RP: Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial. N Engl J Med 308:113, 1983
224. Gluckman E, Esperou-Bourdeau H, Baruchel A, Boogaerts M, Briere J, Donadio D, Leverger G, Leporrier M, Reiffers J, Janvier M, Michallet M, Stryckmans P: Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 79:2540, 1992
225. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL, Ledbetter JA, Singh C, Tepper MA: Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792, 1992
226. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia and lymphoma. Hum Immunol 29:79, 1990
227. Antin J, Bierer N, Smith B, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E, Reichert TA, Blythman H, Bouloux C, Rappeport JM, Burakoff SJ, Weinstein HJ: Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: Effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 78:1464, 1991
228. Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C. Murray K, Hunter J, Baxter-Lowe LA, Gottschall JL, Oldham K, Anderson T, Camitta B, Menitove J: Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 322:485, 1990
229. Bacigalupo A, Hows J, Gordon-Smith EC, Gluckman E, Van Lint MT, Congiu M, James DCO, Barrett AJ, Gmur J, De-Planque MM, Siimes MA, Toivanen A, Ringden O, Marmont AM, for the Working Party of the EBMTG: Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: A report of the BMT Working Party. Bone Marrow Transplant 3:531, 1988
230. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, Sanders JE, Stewart P, Buckner CD, Storb R, Thomas ED, Hansen JA: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313:765, 1985
231. Beatty PG, Anasetti C, Hansen JA, Longton GM, Sanders JE, Martin PJ, Mickelson EM, Choo SY, Petersdorf EW, Pepe MS, Appelbaum FR, Bearman SI, Buckner CD, Clift RA, Petersen FB, Singer J, Stewart PS, Storb RF, Sullivan KM, Tesler MC, Witherspoon RP, Thomas ED: Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 81:249, 1993
232. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806, 1988
233. Herve P, Cahn JY, Flesch M, Plouvier E, Racadot E, Noir A, Couteret Y, Goldstein G, Bernard A, Lenys R, Bresson JL, Leconte des Floris R, Peters A: Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement. Blood 69:388, 1987
234. Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593, 1993
235. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, LeBlond V, Michaller M, Dreyfus F, Ifrath N, Bordigoni A: Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukaemias. Lancet 2:175, 1987
236. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120, 1991
237. McGlave P, Bartch G, Anasetti C, Ash R, Beatty P, Gajewski J, Kernan NA: Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the national marrow donor program. Blood 81:543, 1993
238. Pirsch JD, Maki DG: Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow: Increased susceptibility to fungal infections. Ann Intern Med 104:619, 1986
239. van Bekkum DW, Lowenberg B: Graft-versus host disease, in van Bekkum DW (ed): Bone Marrow Transplantation: Biological Mechanisms and Clinical Practice. New York, NY, Dekker, 1985, p 147
240. Azuma M, Cayabyab M, Phillips JH, Lanier LL: Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol 150:2091, 1993
241. Harding FA, Allison JP: CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 177:1791, 1993
242. de Waal Malefyt R, Verma S, Bejarano MT, Ranes-Goldberg M, Hill M, Spits H: CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/ B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes. Eur J Immunol 23:418, 1993
243. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J, Terasaki P, Billing R, Feig S: Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. Ann Intern Med 105:20, 1986
244. Parmiani G: Tumor immunity as autoimmunity: Tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today 14:536, 1993